Antitumor efficacy of the oncolytic peptide LTX-315 in genetic mouse models that resist conventional chemo-and immunotherapeutic treatments
MJ Pittet, HW Liao, B Sveinbjørnsson, Ø Rekdal - 2018 - AACR
LTX-315 is an oncolytic peptide that induces immunogenic cancer cell death and is currently
evaluated in phase 1 clinical trials for its ability to trigger recruitment of tumor-specific T cells
to tumors. Previous experimental studies identified LTX-3159s ability to control cancer in …
evaluated in phase 1 clinical trials for its ability to trigger recruitment of tumor-specific T cells
to tumors. Previous experimental studies identified LTX-3159s ability to control cancer in …
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论